Observational studyPloS one2026
Real-world outcomes after switching to faricimab in treatment-resistant diabetic macular edema: A 1-year observational study with choroidal thickness assessment.
Observational study in PloS one, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Approximately 40% of diabetic macular edema (DME) cases are resistant to conventional anti-vascular endothelial growth factor (VEGF) therapy. Although faricimab (an antibody against VEGF-A and angiopoietin-2 [Ang-2]) has shown efficacy in treatment-naïve DME, real-world evidence on switching strategies in resistant cases remains limited. We evaluated the 1‑year real‑world effectiveness of switching to faricimab in resistant DME and explored central choroidal thickness (CCT) changes and their relationship to retinal and choroidal responses. This retrospective study included 28 eyes from 19 patients with treatment-resistant DME who switched from aflibercept or ranibizumab to faricimab between May 2022 and August 2023. Central retinal thickness (CRT), CCT, best-corrected visual acuity (BCVA), and injection frequency were evaluated 1 year before, immediately before, and 1 year post-switching. Mean CRT significantly decreased from pre-switching levels of 453 ± 112 μm to 322 ± 60 μm 1-year post-switching (28.9% reduction). The dry macula rate (CRT ≤ 325 μm) was achieved in 53.6% of eyes at 1 year. Injection frequency was significantly higher in the year after switching than in the year before switching (3.5 vs. 5 injections). LogMAR BCVA showed no significant change (0.31 ± 0.27 vs. 0.34 ± 0.32). Ellipsoid zone (EZ)/external limiting membrane (ELM) disruption increased from 28.6% at 1 year before switching to 35.7% immediately before switching, with minimal progression to 39.3% at 1 year post-switching. Mean CCT demonstrated no significant change (238 ± 82 μm vs. 230 ± 62 μm). Faricimab achieved significant anatomical improvements in resistant DME supporting its efficacy in real-world practice. Stable CCT may indicate preserved choroidal perfusion and represent a favorable characteristic of dual VEGF-A and Ang-2 inhibition. The potential suppression of the outer retinal structural deterioration may represent a marker of vascular health during chronic anti-VEGF therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.